A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
A Phase I Study to Evaluate the Effects of Multiple-dose D-1553 on Pharmacokinetics of Single-dose Midazolam, Caffeine, Rosuvastatin, Furosemide and Digoxin, and to Evaluate the Effects of Multiple-dose Itraconazole and Omeprazole on Pharmacokinetics of Single-dose D-1553 in Healthy Male Subjects
Sponsor: InventisBio Co., Ltd
This PHASE1 trial investigates Healthy Male and is currently completed. InventisBio Co., Ltd leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- InventisBio Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .